These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2052359)

  • 1. Molecular characterization of human trk proto-oncogene product monoclonal antibodies.
    Eager KB
    Oncogene; 1991 May; 6(5):819-24. PubMed ID: 2052359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic activation of the tyrosine kinase domain of the human trk proto-oncogene by fusion to a cell adhesion molecule.
    Albor A; Thraves PJ; Dritschilo A; Notario V
    Oncogene; 1996 Oct; 13(8):1755-63. PubMed ID: 8895522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas.
    Greco A; Pierotti MA; Bongarzone I; Pagliardini S; Lanzi C; Della Porta G
    Oncogene; 1992 Feb; 7(2):237-42. PubMed ID: 1532241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of trk receptors in the developing and adult human central and peripheral nervous system.
    Muragaki Y; Timothy N; Leight S; Hempstead BL; Chao MV; Trojanowski JQ; Lee VM
    J Comp Neurol; 1995 Jun; 356(3):387-97. PubMed ID: 7642800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185.
    McKenzie SJ; Marks PJ; Lam T; Morgan J; Panicali DL; Trimpe KL; Carney WP
    Oncogene; 1989 May; 4(5):543-8. PubMed ID: 2566965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel modular mosaic of cell adhesion motifs in the extracellular domains of the neurogenic trk and trkB tyrosine kinase receptors.
    Schneider R; Schweiger M
    Oncogene; 1991 Oct; 6(10):1807-11. PubMed ID: 1656363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular genetic characterization of epitope-specific monoclonal antibodies against the myc family proteins.
    Ikegaki N; Kennett RH
    Oncogene; 1990 Mar; 5(3):397-403. PubMed ID: 1690381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for non-covalent clusters of the c-met proto-oncogene product.
    Faletto DL; Tsarfaty I; Kmiecik TE; Gonzatti M; Suzuki T; Vande Woude GF
    Oncogene; 1992 Jun; 7(6):1149-57. PubMed ID: 1317541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational analysis of conserved residues in the tyrosine kinase domain of the human trk oncogene.
    Mitra G
    Oncogene; 1991 Dec; 6(12):2237-41. PubMed ID: 1837350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of human and viral ets genes in E. coli production of human ets-2-specific monoclonal antibodies.
    Seth A; Watson DK; Fujiwara S; Showalter SD; Papas TS
    Oncogene Res; 1989; 5(1):61-6. PubMed ID: 2674859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.
    Fendly BM; Winget M; Hudziak RM; Lipari MT; Napier MA; Ullrich A
    Cancer Res; 1990 Mar; 50(5):1550-8. PubMed ID: 1689212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfection of TRK-A into human neuroblastoma cells restores their ability to differentiate in response to nerve growth factor.
    Lavenius E; Gestblom C; Johansson I; Nånberg E; Påhlman S
    Cell Growth Differ; 1995 Jun; 6(6):727-36. PubMed ID: 7669728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological determinants of nerve growth factor involved in p140trk (Trk) receptor binding.
    Nanduri J; Vroegop SM; Buxser SE; Neet KE
    J Neurosci Res; 1994 Mar; 37(4):433-44. PubMed ID: 7517456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic activation of the human trk proto-oncogene by recombination with the ribosomal large subunit protein L7a.
    Ziemiecki A; Müller RG; Fu XC; Hynes NE; Kozma S
    EMBO J; 1990 Jan; 9(1):191-6. PubMed ID: 2403926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation of the human neu protein facilitates down-modulation by monoclonal antibodies.
    van Leeuwen F; van de Vijver MJ; Lomans J; van Deemter L; Jenster G; Akiyama T; Yamamoto T; Nusse R
    Oncogene; 1990 Apr; 5(4):497-503. PubMed ID: 1970152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The trk oncogene abrogates growth factor requirements and transforms hematopoietic cells.
    Katzav S; Martin-Zanca D; Barbacid M; Hedge AM; Isfort R; Ihle JN
    Oncogene; 1989 Sep; 4(9):1129-35. PubMed ID: 2674855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human TRK proto-oncogene maps to chromosome 1q32-q41.
    Miozzo M; Pierotti MA; Sozzi G; Radice P; Bongarzone I; Spurr NK; Della Porta G
    Oncogene; 1990 Sep; 5(9):1411-4. PubMed ID: 2216464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-function analyses of the kit receptor for the steel factor.
    Blechman JM; Lev S; Givol D; Yarden Y
    Stem Cells; 1993 Jul; 11 Suppl 2():12-21. PubMed ID: 7691317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies to the amino-terminal sequence of the c-yes gene product as specific probes of its expression.
    Sukegawa J; Akatsuka T; Sugawara I; Mori S; Yamamoto T; Toyoshima K
    Oncogene; 1990 Apr; 5(4):611-4. PubMed ID: 2183163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the NTRK1 genomic region involved in chromosomal rearrangements generating TRK oncogenes.
    Greco A; Mariani C; Miranda C; Pagliardini S; Pierotti MA
    Genomics; 1993 Nov; 18(2):397-400. PubMed ID: 8288244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.